| 000 | 01770 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515052516.0 | ||
| 264 | 0 | _c20070209 | |
| 008 | 200702s 0 0 eng d | ||
| 022 | _a1557-2501 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aApplegate, Robert J | |
| 245 | 0 | 0 |
_aPCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients. _h[electronic resource] |
| 260 |
_bThe Journal of invasive cardiology _cDec 2006 |
||
| 300 |
_a604-13 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngina, Unstable _xdrug therapy |
| 650 | 0 | 4 | _aAngioplasty, Balloon, Coronary |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aEptifibatide |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyocardial Infarction _xdrug therapy |
| 650 | 0 | 4 |
_aPeptides _xadministration & dosage |
| 650 | 0 | 4 |
_aPlatelet Activation _xdrug effects |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGrabarczyk, Mark A | |
| 700 | 1 | _aSane, David C | |
| 700 | 1 | _aSacrinty, Matthew T | |
| 700 | 1 | _aGoodin, Jason E | |
| 700 | 1 | _aStatonk, G Sidney | |
| 700 | 1 | _aBaki, Talal T | |
| 700 | 1 | _aGandhi, Sanjay K | |
| 700 | 1 | _aKutcher, Michael A | |
| 700 | 1 | _aLittle, William C | |
| 773 | 0 |
_tThe Journal of invasive cardiology _gvol. 18 _gno. 12 _gp. 604-13 |
|
| 999 |
_c16764473 _d16764473 |
||